Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tamara A Kucaba

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2009
Activation-induced CD154 expression abrogates tolerance induced by apoptotic cellsPrajwal Gurung, Tamara A Kucaba, Thomas A Ferguson, et al.
Human Immunology|August 30, 2008
Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cellsErik L Brincks, Tamara A Kucaba, Kevin L Legge, et al.
Journal of Leukocyte Biology|September 3, 2010
TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletionPrajwal Gurung, Tamara A Kucaba, Stephen P Schoenberger, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2014
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cellsBritnie R James, Erik L Brincks, Tamara A Kucaba, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2008
CD8 T cells utilize TRAIL to control influenza virus infectionErik L Brincks, Arna Katewa, Tamara A Kucaba, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 21, 2010
Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cellsThomas S Griffith, Erik L Brincks, Prajwal Gurung, et al.
Nanoscale|November 8, 2018
Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapyHyunjoon Kim, Drishti Sehgal, Tamara A Kucaba, et al.
ACS Medicinal Chemistry Letters|November 21, 2017
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8Peter Larson, Tamara A Kucaba, Zhengming Xiong, et al.
ACS Pharmacology & Translational Science|January 15, 2026
Toll-Like Receptor 7/8 Antagonist Promotes Interleukin-10-Mediated Anti-inflammatory TherapyGrahmm A Funk, Jin Xie, Tamara A Kucaba, et al.
Molecular Pharmaceutics|January 9, 2019
Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based NanovaccineHyunjoon Kim, Vidhi Khanna, Tamara A Kucaba, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2009
Activation-induced CD154 expression abrogates tolerance induced by apoptotic cellsPrajwal Gurung, Tamara A Kucaba, Thomas A Ferguson, et al.
Human Immunology|August 30, 2008
Influenza-induced expression of functional tumor necrosis factor-related apoptosis-inducing ligand on human peripheral blood mononuclear cellsErik L Brincks, Tamara A Kucaba, Kevin L Legge, et al.
Journal of Leukocyte Biology|September 3, 2010
TRAIL-expressing CD8+ T cells mediate tolerance following soluble peptide-induced peripheral T cell deletionPrajwal Gurung, Tamara A Kucaba, Stephen P Schoenberger, et al.
Cancer Immunology, Immunotherapy : CII|April 9, 2014
Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cellsBritnie R James, Erik L Brincks, Tamara A Kucaba, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2008
CD8 T cells utilize TRAIL to control influenza virus infectionErik L Brincks, Arna Katewa, Tamara A Kucaba, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 21, 2010
Systemic immunological tolerance to ocular antigens is mediated by TRAIL-expressing CD8+ T cellsThomas S Griffith, Erik L Brincks, Prajwal Gurung, et al.
Nanoscale|November 8, 2018
Acidic pH-responsive polymer nanoparticles as a TLR7/8 agonist delivery platform for cancer immunotherapyHyunjoon Kim, Drishti Sehgal, Tamara A Kucaba, et al.
ACS Medicinal Chemistry Letters|November 21, 2017
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8Peter Larson, Tamara A Kucaba, Zhengming Xiong, et al.
ACS Pharmacology & Translational Science|January 15, 2026
Toll-Like Receptor 7/8 Antagonist Promotes Interleukin-10-Mediated Anti-inflammatory TherapyGrahmm A Funk, Jin Xie, Tamara A Kucaba, et al.
Molecular Pharmaceutics|January 9, 2019
Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based NanovaccineHyunjoon Kim, Vidhi Khanna, Tamara A Kucaba, et al.
Pageof 4